Meta-analysis of anti-VEGF class adverse events from three double-blind (db), placebo (pbo)-controlled phase III trials with IV aflibercept (Afl).
Josep Tabernero
Consultant or Advisory Role - Regeneron; Roche; Sanofi
Carmen Joseph Allegra
Consultant or Advisory Role - Sanofi
Philippe R Rougier
Honoraria - Amgen; Keocyt; Merck Serono; Novartis; Pfizer; Roche; Sanofi
Research Funding - Roche
Giorgio Scagliotti
Honoraria - AstraZeneca; Lilly; Pfizer; Roche
Philip Agop Philip
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Radek Lakomy
Research Funding - Sanofi
Rodryg Ramlau
No relevant relationships to disclose
Sylvie Assadourian
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Soazig Chevalier
Employment or Leadership Position - Sanofi
Eric Van Cutsem
Research Funding - Sanofi (I)